Rendl Gundula, Schweighofer-Zwink Gregor, Sorko Stefan, Gallowitsch Hans-Jürgen, Hitzl Wolfgang, Reisinger Diana, Pirich Christian
Department of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Müllner Hauptstr. 48, 5020 Salzburg, Austria.
Department of Nuclear Medicine and Endocrinology, PET/CT Centre, Klinikum Klagenfurt am Wörthersee, 9020 Klagenfurt, Austria.
Cancers (Basel). 2022 Apr 7;14(8):1868. doi: 10.3390/cancers14081868.
Background: We aimed to compare the established metabolic response criteria PERCIST and EORTC for their applicability and predictive value in terms of clinical response assessment early after the initiation of lenvatinib therapy in patients with metastatic radioiodine-refractory (RAI) thyroid cancer (TC). Methods: In 25 patients treated with lenvatinib, baseline and 4-month follow-up F-18 FDG PET/CT images were analyzed using PERCIST 1.0, modified PERCIST (using SUVpeak or SUVmax) and EORTC criteria. Two groups were defined: disease control (DC) and progressive disease (PD), which were correlated with PFS and OS. Results: PERCIST, mPERCIST, PERCISTmax and EORTC could be applied in 80%, 80%, 88% and 100% of the patients based on the requirements of lesion assessment criteria, respectively. With PERCIST, mPERCIST, PERCISTmax and EORTC, the patients classified as DC and PD ranged from 65 to 68% and from 32 to 35%, respectively. Patients with DC exhibited a longer median PFS than patients with PD for EORTC (p < 0.014) and for PERCIST and mPERCIST (p = 0.037), respectively. Conclusion: EORTC and the different PERCIST criteria performed equally regarding the identification of patients with PD requiring treatment changes. However, the applicability of PERCIST 1.0 using SULpeak seems restricted due to the significant proportion of small tumor lesions.
我们旨在比较已确立的代谢反应标准PERCIST和欧洲癌症研究与治疗组织（EORTC）标准，以评估它们在转移性放射性碘难治性（RAI）甲状腺癌（TC）患者中，在乐伐替尼治疗开始后早期进行临床反应评估时的适用性和预测价值。方法：对25例接受乐伐替尼治疗的患者，使用PERCIST 1.0、改良PERCIST（使用SUVpeak或SUVmax）和EORTC标准分析基线和4个月随访的F-18 FDG PET/CT图像。定义了两组：疾病控制（DC）和疾病进展（PD），并将其与无进展生存期（PFS）和总生存期（OS）相关联。结果：根据病变评估标准的要求，PERCIST、mPERCIST、PERCISTmax和EORTC分别可应用于80%、80%、88%和100%的患者。使用PERCIST、mPERCIST、PERCISTmax和EORTC，分类为DC和PD的患者分别为65%至68%和32%至35%。对于EORTC（p < 0.014）以及PERCIST和mPERCIST（p = 0.037），DC患者的中位PFS均长于PD患者。结论：在识别需要改变治疗的PD患者方面，EORTC和不同的PERCIST标准表现相当。然而，由于小肿瘤病灶比例较高，使用SULpeak的PERCIST 1.0的适用性似乎受到限制。
